I have Multiple Sclerosis, a condition that profoundly impacts every aspect of my life. Managing this disease requires a combination of treatments, and for many like myself, Kesimpta and Ocrevus are imperative. Currently, these life-changing medications are available through the Pharmaceutical Benefits Scheme (PBS) in Australia, which makes them affordable and accessible for the thousands who rely on them every day.

However, there is a looming threat that these essential medications might be removed from the PBS. The impact of such a decision would be devastating, as it would make Kesimpta and Ocrevus unaffordable for many Australians living with Multiple Sclerosis (MS). Most individuals with MS cannot use alternatives like Tysabri due to the risk of the John Cunningham virus, a potentially fatal side effect. Without access to Kesimpta and Ocrevus, countless Australians could suffer severe physical, mental, and financial hardships.

Multiple Sclerosis is a chronic illness that requires ongoing and comprehensive treatment. Research shows that in Australia, around 25,000 people live with MS, facing challenges every day to maintain their quality of life. The cost of MS medications without PBS support could exceed tens of thousands of dollars annually, putting an insurmountable financial burden on affected individuals and families.

Access to affordable medication is not just a health issue—it's a matter of human dignity and equality. All Australians deserve the right to live their lives with as much normalcy and dignity as possible, and keeping these medications on the PBS is a vital part of that right.

We urge the Australian government to reconsider any plans that would remove Kesimpta and Ocrevus from the Pharmaceutical Benefits Scheme. Let's stand together to protect access to these essential medications for all who need them. Please sign this petition and support those of us who depend on Kesimpta and Ocrevus to maintain our health and quality of life.